Atara Biotherapeutics (NASDAQ:ATRA) Lifted to Outperform at Mizuho

Mizuho upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a neutral rating to an outperform rating in a report released on Friday morning, Benzinga reports. They currently have $18.00 price objective on the biotechnology company’s stock, down from their prior price objective of $25.00.

Other research analysts also recently issued research reports about the stock. HC Wainwright reissued a neutral rating on shares of Atara Biotherapeutics in a report on Wednesday, May 22nd. StockNews.com assumed coverage on Atara Biotherapeutics in a research note on Wednesday, June 26th. They set a hold rating for the company. Canaccord Genuity Group reaffirmed a buy rating and issued a $13.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, August 13th. Finally, The Goldman Sachs Group decreased their price objective on Atara Biotherapeutics from $12.50 to $11.00 and set a sell rating on the stock in a report on Wednesday, July 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Hold and a consensus price target of $185.50.

Atara Biotherapeutics Trading Up 2.6 %

Shares of ATRA opened at $7.19 on Friday. The business’s 50 day moving average is $9.46 and its 200 day moving average is $14.78. Atara Biotherapeutics has a 12-month low of $4.96 and a 12-month high of $49.00. The company has a market capitalization of $34.63 million, a PE ratio of -0.13 and a beta of 0.52.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The firm had revenue of $28.64 million for the quarter, compared to analysts’ expectations of $48.30 million. Equities research analysts predict that Atara Biotherapeutics will post -15.75 earnings per share for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics in the 2nd quarter worth approximately $53,000. Cubist Systematic Strategies LLC purchased a new position in Atara Biotherapeutics during the second quarter worth $79,000. Delap Wealth Advisory LLC bought a new position in Atara Biotherapeutics during the first quarter valued at $29,000. Vontobel Holding Ltd. purchased a new stake in shares of Atara Biotherapeutics in the fourth quarter valued at $41,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Atara Biotherapeutics by 29.3% in the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 86,842 shares during the last quarter. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.